University of Medicine and Pharmacy "Carol Davila", Bucharest - Pediatric Chair; 37 Dionisie Lupu Street, Bucharest, Romania.
National Institute for Mother and Child Health "Alessandrescu-Rusescu", 120 Lacul Tei Avenue, Bucharest, Romania.
Biomed Res Int. 2020 Aug 17;2020:2102401. doi: 10.1155/2020/2102401. eCollection 2020.
The aim of the study was to evaluate serum Endocan and Lumican levels as biomarkers for pediatric Nonalcoholic Fatty Liver Disease (NAFLD) and to explore their associations with pediatric cardiometabolic risk factors. We conducted a cross-sectional study on 68 pediatric obese and overweight (O&O) patients. Ten healthy controls were recruited. Serum Lumican and Endocan levels were analyzed using ELISA kits. O&O patients had lower levels of Endocan compared to healthy controls ( < 0.001). There were no differences between serum Endocan levels in O&O patients with NAFLD and those without ( = 0.53). Patients considered having Nonalcoholic Steatohepatitis (NASH) had lower Endocan levels compared to O&O patients without NASH ( = 0.026). Patients with metabolic syndrome had lower levels of Endocan ( = 0.003). There were no significant differences between serum Lumican levels in O&O children compared to healthy controls. Lumican levels were higher in patients with hypertension ( = 0.04). In O&O patients, Lumican levels were negatively correlated with Endocan levels ( = -0.37, = 0.002). Endocan seems a promising biomarker for the evaluation of pediatric NASH. Lumican was not confirmed as a biomarker for NAFLD in our cohort but was associated with higher arterial pressure. Low Endocan levels are accompanied by high serum Lumican levels, and this could be an early signature of cardiometabolic risk.
本研究旨在评估血清 Endocan 和 Lumican 水平作为儿科非酒精性脂肪性肝病 (NAFLD) 的生物标志物，并探讨它们与儿科心脏代谢危险因素的关系。我们对 68 例肥胖和超重的儿科患者进行了横断面研究。招募了 10 名健康对照者。使用 ELISA 试剂盒分析血清 Lumican 和 Endocan 水平。与健康对照组相比，肥胖和超重患儿的 Endocan 水平较低（<0.001）。NAFLD 与非 NAFLD 肥胖和超重患儿的血清 Endocan 水平无差异（=0.53）。患有非酒精性脂肪性肝炎（NASH）的患者的 Endocan 水平低于无 NASH 的肥胖和超重患儿（=0.026）。患有代谢综合征的患者的 Endocan 水平较低（=0.003）。与健康对照组相比，肥胖和超重患儿的血清 Lumican 水平无显著差异。高血压患者的 Lumican 水平较高（=0.04）。在肥胖和超重患儿中，Lumican 水平与 Endocan 水平呈负相关（=−0.37，=0.002）。Endocan 似乎是评估儿科 NASH 的有前途的生物标志物。在我们的队列中，Lumican 未被确认为 NAFLD 的生物标志物，但与较高的动脉压有关。低 Endocan 水平伴随着高血清 Lumican 水平，这可能是心脏代谢风险的早期特征。
